시장보고서
상품코드
1091938

항응고제 시장 : 세계 산업 동향, 점유율, 규모, 성장률, 기회, 예측(2022-2027년)

Anticoagulants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027

발행일: | 리서치사: IMARC Services Private Limited | 페이지 정보: 영문 145 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 항응고제 시장 규모는 2021년에 340억 달러를 기록했습니다. 이 시장은 향후 2022-2027년 10.2%의 CAGR로 확대하며, 2027년에는 608억 달러에 달할 것으로 예측되고 있습니다.

세계의 항응고제 시장에 대해 조사했으며, 시장의 개요와 약제 클래스별, 투여 경로별, 유통 채널별, 용도별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서문

제2장 범위와 조사 방법

제3장 개요

제4장 서론

제5장 세계의 항응고제 시장

  • 시장 개요
  • 시장 실적
  • COVID-19의 영향

제6장 시장 내역, 약제 클래스별

  • 신규 경구 항응고제(NOAC)
  • 헤파린과 저분자량 헤파린(LMWH)
  • 비타민 K 길항제
  • 기타

제7장 시장 내역, 투여 경로별

  • 경구
  • 주사

제8장 시장 내역, 유통 채널별

  • 원내 약국
  • 소매 약국
  • 온라인 스토어
  • 기타

제9장 시장 내역, 용도별

  • 심방세동과 심장 발작
  • 뇌졸중
  • 심부정맥혈전증(DVT)
  • 폐색전증(PE)
  • 기타

제10장 시장 내역, 지역별

  • 북미
  • 아시아태평양
  • 유럽
  • 라틴아메리카
  • 중동·아프리카

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter의 산업 분석

제14장 가격 분석

제15장 경쟁 구도

  • 시장 구조
  • 주요 기업
  • 주요 기업의 개요
    • Alexion Pharmaceuticals Inc
    • Aspen Holdings
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Daiichi Sankyo Company Limited
    • Dr. Reddy's Laboratories Ltd
    • GlaxoSmithKline plc
    • Johnson & Johnson Private Limited
    • Pfizer Inc.
    • Sanofi
KSA 22.07.04

The global anticoagulants market reached a value of US$ 34.0 Billion in 2021. Looking forward, IMARC Group expects the market to reach US$ 60.8 Billion by 2027, exhibiting a CAGR of 10.2% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic. These insights are included in the report as a major market contributor.

Blood clots form when blood thickens and forms a semi-solid mass in any part of the body. This causes serious problems, such as stroke, heart attack, pulmonary embolism, transient ischemic attacks, and deep vein thrombosis (DVT). As a result, doctors around the world are prescribing anticoagulant drugs to people who are at a high risk of clot formation. These drugs help in thinning blood, preventing or reducing blood clotting, and prolonging the clotting time. They are usually available in capsule or tablet form, including warfarin, rivaroxaban, dabigatran and apixaban.

Anticoagulants Market Trends:

Recent research indicates that hypercoagulability in individuals affected by the coronavirus disease (COVID-19) pandemic can be one of the leading causes of mortality worldwide. As a result, its surging cases are positively influencing the demand for anticoagulant drugs to treat the thrombotic condition among critically ill or hospitalized patients. Moreover, certain risk factors, such as extended sitting, smoking, trauma, blood disorders, and autoimmune diseases, can cause blood clotting in different parts of the body. This, in confluence with the increasing prevalence of human immunodeficiency virus (HIV), hepatitis C, Lyme disease, obesity, cancer, and chronic inflammation, represents another significant factor strengthening the growth of the market. Apart from this, the growing aging population across the globe is resulting in the escalating demand for surgical services. Surgeries often require prolonged bed rest, which, in turn, increases the risk of blood clotting and the overall sales of anticoagulant drugs. Furthermore, the improving diagnosis rates and the escalating demand for target therapeutics are fueling the market growth. The emergence of online pharmacies is also driving the demand for anticoagulant drugs around the world.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global anticoagulants market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on drug class, route of administration, distribution channel and application.

Breakup by Drug Class:

  • Novel Oral Anticoagulants (NOACs)
  • Heparin and Low Molecular Weight Heparin (LMWH)
  • Vitamin K Antagonist
  • Others

Breakup by Route of Administration:

  • Oral Anticoagulant
  • Injectable Anticoagulant

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Stores
  • Others

Breakup by Application:

  • Atrial Fibrillation and Heart Attack
  • Stroke
  • Deep Vein Thrombosis (DVT)
  • Pulmonary Embolism (PE)
  • Others

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Alexion Pharmaceuticals Inc, Aspen Holdings, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Dr. Reddy's Laboratories Ltd, GlaxoSmithKline plc, Johnson & Johnson Private Limited, Pfizer Inc. and Sanofi.

Key Questions Answered in This Report:

  • How has the global anticoagulants market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global anticoagulants market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What is the breakup of the market based on the application?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global anticoagulants market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Anticoagulants Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Novel Oral Anticoagulants (NOACs)
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Heparin and Low Molecular Weight Heparin (LMWH)
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Vitamin K Antagonist
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral Anticoagulant
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Injectable Anticoagulant
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Online Stores
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by Application

  • 9.1 Atrial Fibrillation and Heart Attack
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Stroke
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Deep Vein Thrombosis (DVT)
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Pulmonary Embolism (PE)
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Alexion Pharmaceuticals Inc
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Aspen Holdings
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Bayer AG
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Boehringer Ingelheim International GmbH
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Bristol-Myers Squibb Company
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Daiichi Sankyo Company Limited
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Dr. Reddy's Laboratories Ltd
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 GlaxoSmithKline plc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Johnson & Johnson Private Limited
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제